@FinlaysonMac @MM_Hub @UABDeptMed I completely agree that it’s always disappointing when it happens. But unfortunately when we design a phase 1 study and we are not aware of the safety profile of the agent, the sponsor errs on side of caution. I hope your wife is able to join the study in the future.

@MyelomaTeacher @HealthTree Thank you for having me!

@JoshuaRichterMD Glad to have a friend in this scary backstage 😳😳😳

@SurbhiSidanaMD @VincentRK @thanosdimop Thanks @SurbhiSidanaMD, encouraging results in this space, we will be updating the PFS and OS data on Monday (slightly different)

@mdbrunocosta @VincentRK @MDAndersonNews Congrats @mdbrunocosta

We showed identical MRD responses as Quadruplet+ASCT and were able to spare a quarter of patients the toxicity of ASCT. Important to follow long term outcomes but so far so good! Larger studies Master-2 and MIDAS if further answer this and other important qs. But it can be done!

@SLentzsch @DrKrinaPatel @MDAndersonNews @SagarLonialMD @ninashah33 @thanosdimop Fantastic, congratulations @DrKrinaPatel so well deserved

@rajshekharucms @columbiacancer Congratulations, Raj!

@szusmani @richaparikh36 @cricketworldcup @sridevirajeeve @hhashmi87 Wow, awesome you guys got to experience this in real time 😊👍

@End_myeloma @TMSchmidtMD @RahulBanerjeeMD @Phhersh @UCSFCancer Similar case with primary refractory t(11;14) MM never responded to anything g including Dara, PR to ven/dex and straight to CART and responded for >2 years and then now on investigational CART for >1y

@JoshuaRichterMD The absolute best! Major FOMO

No pressure right! Debating @Myeloma_Doc

Thanks @GKaurMD for the amazing kebabs delivered since she couldn’t take me out while in Dallas, the sweetest 🥹🫠

@GKaurMD @JKaufmanMD @Myeloma_Doc @rabonour1 @DrKrinaPatel @ldandersonjr @jmikhaelmd @GreatDebatesCME @RahulBanerjeeMD A very important and fun debate! @JKaufmanMD @GKaurMD - CART in earlier lines Y/N?

@AnnetteHay1 @HiraSMian @CDNCancerTrials Awesome! Congratulations Hira!

@Rfonsi1 @HiraSMian @VincentRK @OncLive @MayoMyeloma @MayoClinic Congratulations! Wonderful news!

@KRejeski describing cytopenias post CART across disease states and showing elegant work in showing not all cytopenias are created equal and recurrent neutrophil dips in clinic maybe a good thing! #iwCART

@SLentzsch That’s what we need, I have used in a few cases if we can get insurance approval.

@eric_facs @ShuchiGulati @OSUCCC_James @OSU_Urology @OhioStateMedOnc @UCDavisHealth Such a rockstar!